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Background: Novel second-line treatments are needed for patients with advanced urothelial cancer (UC). Interim analysis of
the phase III KEYNOTE-045 study showed a superior overall survival (OS) benefit of pembrolizumab, a programmed death 1
inhibitor, versus chemotherapy in patients with advanced UC that progressed on platinum-based chemotherapy. Here we
report the long-term safety and efficacy outcomes of KEYNOTE-045.
Patients and methods: Adult patients with histologically/cytologically confirmed UC whose disease progressed after first-line,
platinum-containing chemotherapy were enrolled. Patients were randomly assigned 1 : 1 to receive pembrolizumab [200mg every
3weeks (Q3W)] or investigator’s choice of paclitaxel (175mg/m2 Q3W), docetaxel (75mg/m2 Q3W), or vinflunine (320mg/m2
Q3W). Primary end points were OS and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors, version 1.1
(RECIST v1.1) by blinded independent central radiology review (BICR). A key secondary end point was objective response rate per
RECIST v1.1 by BICR.
Results: A total of 542 patients were enrolled (pembrolizumab, n¼ 270; chemotherapy, n¼ 272). Median follow-up as of
26 October 2017 was 27.7months. Median 1- and 2-year OS rates were higher with pembrolizumab (44.2% and 26.9%,
respectively) than chemotherapy (29.8% and 14.3%, respectively). PFS rates did not differ between treatment arms; however,
1- and 2-year PFS rates were higher with pembrolizumab. The objective response rate was also higher with pembrolizumab
(21.1% versus 11.0%). Median duration of response to pembrolizumab was not reached (range 1.6þ to 30.0þmonths) versus
chemotherapy (4.4months; range 1.4þ to 29.9þmonths). Pembrolizumab had lower rates of any grade (62.0% versus 90.6%)
and grade3 (16.5% versus 50.2%) treatment-related adverse events than chemotherapy.
VC The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
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Conclusions: Long-term results (>2 years’ follow-up) were consistent with those of previously reported analyses,
demonstrating continued clinical benefit of pembrolizumab over chemotherapy for efficacy and safety for treatment of locally
advanced/metastatic, platinum-refractory UC.
Trial registration: ClinicalTrials.gov: NCT02256436.
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Introduction
Until recently, only a few chemotherapies were available for
second-line treatment of patients with platinum-refractory blad-
der cancer, leaving an urgent unmet need in this population.
Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2,
have become a focus of cancer research as targets for immuno-
therapy, culminating in development of monoclonal antibody
immune checkpoint inhibitors. Phase I studies with the PD-1 in-
hibitor pembrolizumab showed clinical antitumor activity in sev-
eral solid tumor types, including previously treated urothelial
cancer (UC) [1, 2]. KEYNOTE-045 (ClinicalTrials.gov,
NCT02256436) is an ongoing, international, randomized, active-
controlled, phase III trial of second-line pembrolizumab versus
investigator’s choice of docetaxel, paclitaxel, or vinflunine in
patients with recurrent advanced UC that has progressed with
platinum-based chemotherapy [3]. Significant overall survival
(OS) benefit relative to chemotherapy with a concomitant im-
provement in tumor response and a favorable adverse event (AE)
profile were reported at the second interim analysis [3]. This was
the first demonstration of survival benefit of any agent over
chemotherapy in this patient population and was the basis for ex-
pansion of indications for pembrolizumab to include patients
with locally advanced or metastatic UC with progressive disease
(PD) during or after platinum-containing chemotherapy [4].
Further analysis of patient-reported outcomes measures in
KEYNOTE-045 revealed that pembrolizumab significantly
prolonged time to deterioration in global health status and
health-related quality-of-life score compared with chemother-
apy, possibly contributing to the reported cost-effectiveness of
this treatment in the USA [5, 6]. Long-term safety and efficacy
outcomes of KEYNOTE-045 are reported herein; median follow-
up was 27.7 months.
Methods
Study design and patient population
This study was conducted in accordance with Good Clinical Practice
guidelines and the Declaration of Helsinki, and the study protocol was
approved by the institutional review boards or ethics committees of all
participating sites. All patients provided written informed consent to par-
ticipate before enrollment.
More detailed methodology is published elsewhere [3]. In brief, adult
patients were enrolled with previously treated (two or fewer lines of sys-
temic chemotherapy for advanced disease) UC of the renal pelvis, ureter,
bladder, or urethra, with predominantly transitional cell features, that
had progressed after first-line, platinum-containing chemotherapy for
advanced disease. All patients had at least one measurable lesion accord-
ing to Response Evaluation Criteria in Solid Tumors, version 1.1
(RECIST v1.1) [7] and an Eastern Cooperative Oncology Group per-
formance status (ECOG PS) score of 0, 1, or 2.
Treatment and assessments
Patients were randomly assigned (1 : 1) to receive either pembrolizumab
200 mg intravenously (i.v.) every 3 weeks (Q3W) or the investigator’s
choice of paclitaxel (175 mg/m2 i.v. Q3W), docetaxel (75 mg/m2 i.v.
Q3W), or vinflunine (320 mg/m2 i.v. Q3W). Randomization was strati-
fied according to the ECOG PS score (0 or 1 versus 2), the presence of
liver metastases (yes versus no), hemoglobin concentration (<10 versus
10 g/dl), and time since the last dose of chemotherapy (<3 versus
3 months). Treatment was open-label and continued until PD per
RECIST v1.1, unacceptable toxicity, patient or investigator decision to
discontinue treatment, or 2 years of pembrolizumab treatment. The ori-
ginal protocol did not allow patient crossover from chemotherapy to
pembrolizumab [3]; however, positive findings of the second interim
analysis [3] led to amendment of the protocol to allow crossover to pem-
brolizumab treatment of patients in the chemotherapy arm who experi-
enced investigator-defined PD per RECIST v1.1 while receiving study
treatment or who, after stopping study treatment, started subsequent
anticancer therapy and then experienced progression.
Tumor response was assessed per RECIST v1.1 by blinded independ-
ent central radiology review (BICR) at week 9, every 6 weeks thereafter
during the first year, and every 12 weeks thereafter. Patients were con-
tacted every 12 weeks for survival assessment. Full assessment schedules
for efficacy and safety are provided elsewhere [3]. All AEs of unknown eti-
ology thought to be associated with pembrolizumab exposure were eval-
uated to determine whether they were of potentially immunologic
etiology [i.e. immune-mediated AEs (imAEs)].
Study end points
Primary end points were OS and progression-free survival (PFS) per
RECIST v1.1 by BICR in all patients and in patients with PD-L1-express-
ing disease according to two thresholds [combined positive score (CPS)
1 and CPS10, determined using the PD-L1 IHC 22C3 pharmDx assay
(Agilent Technologies)]. Secondary end points were safety and tolerabil-
ity of pembrolizumab, objective response rate, and duration of response
(DOR) per RECIST v1.1.
Statistical analysis
Details of statistical analyses are presented elsewhere [3]. The primary ef-
ficacy end points were analyzed using data from the intention-to-treat
(ITT) population, whereas data from the all-patients-as-treated (APaT)
population (all randomly assigned patients who received at least one dose
of study treatment) were analyzed for safety data. Median follow-up was
calculated as median duration from randomization date to data cut-off
date. An exploratory analysis evaluated OS and PFS by best overall re-
sponse. The data cut-off date was 26 October 2017. Safety and tolerability
(assessed by clinical review of AEs, laboratory tests, vital signs, and elec-
trocardiography) were analyzed descriptively.
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Results
Patient disposition and baseline characteristics
Among the ITT population (N¼ 542), 270 patients received
pembrolizumab and 272 received chemotherapy; of those, 266
pembrolizumab and 255 chemotherapy patients composed the
APaT (safety) population (N¼ 521). None of the 255 patients in
the chemotherapy arm completed 2 years of therapy; 26 of the
266 (9.8%) pembrolizumab-treated patients completed 2 years of
therapy and 240 (90.2%) had discontinued treatment at the time
of data cut-off (supplementary Figure S1, available at Annals of
Oncology online). One patient in the chemotherapy arm and 10
patients in the pembrolizumab arm discontinued treatment be-
fore 2 years because they achieved complete response (CR). PD
was the primary reason for discontinuation of pembrolizumab
and chemotherapy (supplementary Figure S1, available at Annals
of Oncology online). Baseline characteristics of the patients were
similar between the two treatment arms [3] (supplementary
Table S1, available at Annals of Oncology online).
Efficacy: overall population
OS and PFS. The median OS was 10.1 months (95% CI 8.0–
12.3 months) with pembrolizumab and 7.3 months (95% CI 6.1–
8.1 months) with chemotherapy [hazard ratio (HR) 0.70; 95% CI
0.57–0.85; P< 0.001]. After a median follow-up of 27.7 months,
the 1-year OS rates were 44.2% and 29.8% and the 2-year OS rates
were 26.9% and 14.3% for pembrolizumab and chemotherapy,
respectively (Figure 1A). Pembrolizumab continued to demon-
strate an OS benefit over chemotherapy in all subgroups exam-
ined (supplementary Figure S2, available at Annals of Oncology
online), including those with visceral disease and liver metastases,
and across the different levels of PD-L1 expression (i.e. CPS <1,
CPS1, CPS<10, and CPS10) and risk groups. Of patients in
the chemotherapy arm still alive at 24 months, including those
who received pembrolizumab per protocol crossover (6/33;
18.2%), 60.6% (20/33) received an immune checkpoint
inhibitor.
There was no statistically significant difference in PFS between
the pembrolizumab and chemotherapy arms (Figure 1B):
2.1 months (95% CI 2.0–2.2 months) versus 3.3 months (95% CI
2.4–3.6 months), respectively (HR 0.96; 95% CI 0.79–1.16;
P¼ 0.31295). However, the 24-month PFS rates were greater in
pembrolizumab-treated patients (12.4%) than in chemotherapy-
treated patients (3.0%).
Objective response. The objective response rate was higher in the
pembrolizumab arm (21.1%) than in the chemotherapy arm
(11.0%), as were the rates of CR (9.3% versus 2.9%) and partial
response (PR; 11.9% versus 8.1%; Table 1). Results for patients
with CPS 10 were 20.3% for pembrolizumab and 6.7% for
chemotherapy. Rates of stable disease (SD) were lower with pem-
brolizumab than with chemotherapy (17.4% versus 33.8%). The
median DOR was longer with pembrolizumab than with chemo-
therapy [not reached (NR; range 1.6þ to 30.0þ months) versus
4.4 months (range 1.4þ to 29.9þ months); Figure 1C].
Furthermore, a greater proportion of pembrolizumab-treated
patients had responses (CR or PR) lasting 6 months [84%
(n¼ 46) versus 47% (n¼ 8)] and 12 months [68% (n¼ 35)
versus 35% (n¼ 5)].
OS and PFS by objective response. An exploratory analysis evalu-
ating OS by objective response showed that OS was prolonged
among patients with CR or PR to pembrolizumab compared with
those who responded to chemotherapy (supplementary Figure
S3A, available at Annals of Oncology online). Among patients
with an objective response, median OS was NR for
pembrolizumab-treated patients and 16.4 months for
chemotherapy-treated patients at data cut-off (supplementary
Figure S3A, available at Annals of Oncology online). Among
patients with SD as best response, median OS was greater with
pembrolizumab than with chemotherapy (supplementary Figure
S3B, available at Annals of Oncology online). The difference in the
median OS of patients with PD as best response did not seem
meaningful between the arms (supplementary Figure S3C, avail-
able at Annals of Oncology online). Additionally, PFS (supple-
mentary Table S2, available at Annals of Oncology online) was
longer for those with an objective response to pembrolizumab
than for those who responded to chemotherapy. No differences
were observed in PFS between treatment arms for those with SD
or no response.
Safety
Treatment-related AEs occurred less frequently among patients
receiving pembrolizumab (62.0%) than among those receiving
chemotherapy (90.6%). The most common (>15% of patients)
were pruritus for the pembrolizumab arm and alopecia, fatigue,
anemia, nausea, constipation, decreased appetite, and neutro-
penia for the chemotherapy arm (Table 2). Treatment-related
serious AEs (SAEs) were reported by 32 (12.0%) patients treated
with pembrolizumab and 57 (22.4%) treated with chemotherapy.
None of the treatment-related SAEs in the pembrolizumab arm
occurred with a frequency of>2%; the most frequently occurring
(in >1% of patients) were colitis (1.9%), pneumonitis (1.9%),
and interstitial lung disease (1.1%). The most frequently occur-
ring treatment-related SAEs in the chemotherapy arm were fe-
brile neutropenia (6.3%), constipation (2.7%), anemia (2.0%),
intestinal obstruction (2.0%), neutropenia (2.0%), and urinary
tract infection (1.6%) (supplementary Table S3, available at
Annals of Oncology online). When evaluated by duration of ex-
posure to treatment (up to 12 months), patients in the chemo-
therapy group had a higher incidence of any grade and grade 3/4
treatment-related AEs than patients in the pembrolizumab group
(supplementary Table S4, available at Annals of Oncology online).
Fewer patients receiving pembrolizumab (6.8%, n¼ 18) than
patients receiving chemotherapy (12.5%, n¼ 32) discontinued
study treatment because of a treatment-related AE. These events
were most commonly pneumonitis (1.9%, n¼ 5) and interstitial
lung disease (0.8%, n¼ 2) with pembrolizumab and peripheral
sensory neuropathy (2.0%, n¼ 5) and peripheral neuropathy
(1.6%, n¼ 4) with chemotherapy.
Immune-mediated AEs were reported by 52 (19.5%) and 17
(6.7%) patients in the pembrolizumab and chemotherapy arms,
respectively, and most were grade 1 or 2 for both treatment arms
(69.2% and 88.2%, respectively). One grade 5 imAE, pneumon-
itis, was considered treatment related and resulted in the death of
Original article Annals of Oncology
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a patient in the pembrolizumab arm. Study discontinuation be-
cause of imAEs occurred in nine (3.4%) patients in the pembroli-
zumab arm and two (0.8%) patients in the chemotherapy arm.
Treatment-related serious imAEs occurred in 16 (6.0%) patients in
the pembrolizumab arm and resulted in treatment discontinuation
in 7 (2.6%) patients; no treatment-related serious imAEs occurred
in the chemotherapy arm. Median time to onset of the first imAE
was longer with pembrolizumab than with chemotherapy
[105 days (range 1–647 days) versus 21 days (range 1–70 days)],
and the average number of imAE episodes per patient was similar
between the treatment arms (1.48 versus 1.29). Four patients in
each treatment arm (<2%) died of what were considered
treatment-related AEs: pneumonitis, urinary tract obstruction,
malignant neoplasm progression, and cause unknown (n¼ 1 each)
with pembrolizumab and septic shock (n¼ 1), sepsis (n¼ 2), and
cause unknown (n¼ 1) with chemotherapy.
Discussion
Until recently, the only approved chemotherapeutic agents avail-
able as second-line therapy were vinflunine, which is associated
with very limited clinical benefit and severe side-effects, and gem-
citabine and taxane, the use of which is supported by consensus
guidelines [8–11]. Although advent of immune checkpoint
inhibitors has improved the outlook for this patient population,
pembrolizumab is the only one for which there is level 1 evidence
from the KEYNOTE-045 study of improved survival, safety, and
quality-of-life compared with chemotherapy [12]. Findings of
the current analysis show continued OS benefit and superior
safety of pembrolizumab over chemotherapy in second-line UC
after >2 years of follow-up. The 24-month OS rate for the pem-
brolizumab arm was 26.9%. Of note, 60.6% of patients in the
chemotherapy arm alive at 24 months received a checkpoint
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inhibitor, which might account for the 24-month OS rate of
14.3% and flattening of the Kaplan–Meier curve for that arm,
which historically has not been observed with chemotherapy
(Figure 1A). Tumor response is greater with pembrolizumab
than with chemotherapy (objective response rate, 21.1% versus
11.0%). Remarkably, after this extended follow-up, median DOR
was still not yet reached with pembrolizumab and was just
4.4 months with chemotherapy.
To date, KEYNOTE-045 is the only phase III study of immuno-
therapy that has more than 2 years of follow-up data to show a
survival benefit over chemotherapy. Analyses of other PD-1/PD-
L1 inhibitors have provided follow-up of>2 years; however, they
have been limited to phase I/II studies [13–15]. Atezolizumab
(PD-L1 inhibitor) monotherapy initially showed promising effi-
cacy in an expansion cohort of a phase I study of predominantly
heavily pretreated patients with metastatic UC (median follow-
up, 37.8 months) [15] and in the phase II IMvigor210 trial (me-
dian follow-up, 29–33 months) [14]. However, these results were
not confirmed in the phase III IMvigor211 study in which atezoli-
zumab did not show a statistically significant difference in OS
compared with chemotherapy (11.1 versus 10.6; HR 0.87; 95% CI
0.63–1.21; P¼ 0.41) after a median follow-up of 17.3 months
[15]. Nivolumab (PD-1 inhibitor) monotherapy also showed
promising efficacy after a follow-up of >2 years in the phase I/II
CheckMate-032 study [13]; however, these results have not yet
been confirmed in a phase III trial. In the KEYNOTE-045 study,
OS benefit with pembrolizumab was seen consistently across all
subgroups, including in patients with liver or visceral metastasis,
all PD-L1 expression levels (i.e. CPS <1, CPS 1, CPS <10, and
CPS 10), all chemotherapies (paclitaxel, docetaxel, and vinflu-
nine), and all across risk groups (supplementary Figure S2, avail-
able at Annals of Oncology online). OS in patients with CPS 10
was significantly longer with pembrolizumab than with chemo-
therapy (8.0 versus 4.9 months; P¼ 0.00122), and DOR was com-
parable with that in the ITT population (NR versus 4.4 months
for both populations).
Role of PD-L1 expression as second-line therapy for UC is un-
certain. Direct comparison between these PD-1/PD-L1 inhibitors
is precluded by use of different assays to establish PD-L1 positiv-
ity [3, 15–17]. PD-L1 expression seemed to predict a greater re-
sponse to nivolumab and to durvalumab in single-arm phase I/II
studies [16, 17]. PD-L1 enrichment reported for atezolizumab in
Table 1. Best overall response assessed based on RECIST v1.1 by blinded
central radiology review
Best overall response Pembrolizumab Chemotherapy
n5 270 n5 272
n % (95% CI)a n % (95% CI)a
Objective response
rate (CRþPR)
57 21.1 (16.4–26.5) 30 11.0 (7.6–15.4)
CR 25 9.3 (6.1–13.4) 8 2.9 (1.3–5.7)
PR 32 11.9 (8.2–16.3) 22 8.1 (5.1–12.0)
SD 47 17.4 (13.1–22.5) 92 33.8 (28.2–39.8)
Disease control
rate (CRþPRþSD)
104 38.5 (32.7–44.6) 122 44.9 (38.8–51.0)
Progressive disease 131 48.5 (42.4–54.7) 90 33.1 (27.5–39.0)
No assessment 31 11.5 (7.9–15.9) 52 19.1 (14.6–24.3)
Nonevaluableb 4 1.5 (0.4–3.7) 8 2.9 (1.3–5.7)
aBased on binomial exact CI method.
bPatients had postbaseline imaging; best overall response was deter-
mined as nonevaluable per RECIST v1.1.
CR, complete response; PR, partial response; RECIST, Response Evaluation
Criteria in Solid Tumors; SD, stable disease.
Table 2. Treatment-related AEs of any grade and grade 3–5 occurring in
>5% of patients (in either treatment arm): all-patients-as-treated
population
Treatment-related
AEs, n (%)
Pembrolizumab Chemotherapy
n5 266 n5255
Any
grade
Grade
3–5a
Any
grade
Grade
3–5a,b
Any 165 (62.0) 44 (16.5) 231 (90.6) 128 (50.2)
Pruritus 52 (19.5) 8 (3.1)
Fatigue 37 (13.9) 71 (27.8)
Nausea 30 (11.3) 62 (24.3)
Decreased appetite 25 (9.4) 43 (16.9)
Diarrhea 24 (9.0) 33 (12.9)
Rash 23 (8.6) 10 (3.9)
Hypothyroidism 19 (7.1) 0
Asthenia 17 (6.4) 36 (14.1)
Pyrexia 17 (6.4) 9 (3.5)
Vomiting 12 (4.5) 25 (9.8)
Arthralgia 9 (3.4) 17 (6.7)
Anemia 8 (3.0) 2 (0.8) 64 (25.1) 24 (9.4)
Constipation 7 (2.6) 52 (20.4)
Stomatitis 5 (1.9) 21 (8.2)
Mucosal
inflammation
4 (1.5) 17 (6.7)
Dysgeusia 3 (1.1) 14 (5.5)
Pain in extremity 3 (1.1) 13 (5.1)
Peripheral sensory
neuropathy
2 (0.8) 28 (11.0)
Neutrophil count
decreased
1 (0.4) 1 (0.4) 37 (14.5) 31 (12.2)
Peripheral
neuropathy
1 (0.4) 27 (10.6)
Edema peripheral 1 (0.4) 19 (7.5)
Leukocyte count
decreased
1 (0.4) 1 (0.4) 19 (7.5) 13 (5.1)
Neutropenia 0 0 40 (15.7) 35 (13.7)
Alopecia 0 96 (37.6)
Febrile neutropenia 0 0 19 (7.5) 19 (7.5)
aCells are left blank if the frequency of occurrence was <5% in both
treatment arms.
bThere was just one grade 5 event (pneumonitis), which occurred in the
pembrolizumab arm (0.4%).
AE, adverse event.
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this indication was confirmed in a phase I study [15] but was not
confirmed in the subsequent phase III IMvigor211 study [18].
Superior objective response rate was observed with pembrolizu-
mab over chemotherapy in patients whose tumors expressed PD-
L1 CPS 10 (20.3% versus 6.7%) and was similar to that in the
overall ITT population. Findings of the KEYNOTE-045 study
have shown that, although tumor response in terms of objective
response rate was similar across all PD-L1 subgroups treated with
pembrolizumab, response rates were higher than was achieved
with chemotherapy. Additional studies comparing pembrolizu-
mab monotherapy, chemotherapy, and combination treatment
with pembrolizumab plus chemotherapy should elucidate the
role of PD-L1 expression in bladder cancer.
Consistent with data from previous pembrolizumab studies,
pembrolizumab was well tolerated in patients with advanced UC
and had a more favorable tolerability profile than chemotherapy.
Treatment-related AEs were more frequent with chemotherapy
(90.6%) than with pembrolizumab (62.0%). Most frequently
observed treatment-related AEs with pembrolizumab in the cur-
rent trial occurred in <20% of patients, whereas many of those
observed with chemotherapy occurred in >20% of patients.
Treatment-related SAEs also occurred more frequently with
chemotherapy (22.4%) than with pembrolizumab (12.0%). The
discontinuation rate from treatment-related AEs in the chemo-
therapy arm (12.5%) was almost double that in the pembrolizu-
mab arm (6.8%).
With >2 years of follow-up, pembrolizumab continues to
demonstrate superior survival over chemotherapy in patients
with advanced UC after failure of platinum-based therapy, irre-
spective of PD-L1 status. These data are consistent with those
underlying approval of pembrolizumab in this patient popula-
tion by health authorities in>60 countries.
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